99mTc-labeled field bean protease inhibitor can function as an efficient tumor detecting agent.

Area of Science:

• Nuclear Medicine
• Radiopharmaceutical Development
• Oncology

Background:

• Field bean protease inhibitor (FBPI) is a potential candidate for tumor targeting.
• Development of novel radiopharmaceuticals is crucial for improved cancer imaging.
• Technetium-99m (99mTc) is a widely used radionuclide for diagnostic imaging.

Purpose of the Study:

• To label purified FBPI with 99mTc and evaluate its efficacy in locating tumors in preclinical models.
• To compare the tumor-targeting ability of 99mTc-FBPI with established radiopharmaceuticals.

Main Methods:

• FBPI was labeled with 99mTc using Sn2+ as a reducing agent, achieving a 95% labeling yield.
• Biodistribution studies were performed in normal Wistar rats to assess blood clearance and excretion pathways.
• In vivo tumor imaging and quantification (tumor-to-muscle ratios) were conducted in rats bearing mammary tumors or C6-gliomas.

Main Results:

• The 99mTc-FBPI complex exhibited rapid blood clearance and was primarily excreted renally and hepatobiliary.
• In C6-glioma models, 99mTc-FBPI achieved tumor-to-muscle ratios 2-5 times higher than conventional agents.
• For mammary tumors, 99mTc-FBPI showed 2-3 fold higher tumor-to-muscle ratios than 99mTc(V)-DMSA and 201TlCl.

Conclusions:

• 99mTc-FBPI demonstrates significant potential as a tumor-specific imaging agent, particularly for gliomas.
• The enhanced tumor uptake and retention suggest FBPI's utility in targeted cancer diagnostics.
• Further investigation into 99mTc-FBPI for various tumor types is warranted.